FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994262466> ?p ?o ?g. }

• W2994262466 abstract "Abstract Cytokines such as TNF α, IFN γ and others have been implicated in the pathogenesis of ineffective hematopoiesis in MDS and are thought to lead to the high rate of apoptosis in hematopoietic progenitors. The p38 Mitogen Activated Protein Kinase (MAPK) is an evolutionary conserved enzyme that is involved in many cellular processes including stress signaling. We have previously shown that the p38 MAP kinase is strongly activated by IFNs, TNF α, TGF β and other inhibitory cytokines in normal primary hematopoietic progenitors and plays an important role in the negative regulation of normal hematopoiesis. In the present study, we determined the role of the p38 MAPK in the pathogenesis of MDS evaluated its inhibition as a potential therapeutic strategy in this disease. p38 MAPK inhibition was achieved by the use of a novel p38 inhibitor - SD-282, a specific inhibitor of p38α MAP kinase. SD-282 performs very similarly in animal and cell models to a p38 inhibitor now in the clinic. We also transfected primary hematopoietic cells with flurescent labeled siRNAs against p38 and successfully downregulated the levels of the protein. Using these approaches, we demonstrate that pharmacological inhibition of the p38 MAPK can reverse the growth inhibitory effects of TNF α and IFN γ on erythroid and myeloid colony formation. This reversal of TNF α mediated inhibition correlates with significant reduction of apoptosis seen in human hematopoeitic progenitors pretreated with p38 inhibitor SD-282. Having established the importance of p38 MAPK in cytokine mediated inhibition of normal hematopoiesis, we performed colony forming assays with bone marrow CD34+ cells from 8 patients with MDS in the presence of either pharmacologic or siRNA based inhibitors of p38. All patients had refractory cytopenias with multilineage dysplasia. Our data indicates that SD-282 treatment strongly enhances both erythroid and myeloid colony formation in MDS CD34+ bone marrow cells in vitro. This increase was not observed when these progenitors were grown in the presence of negative controls - SB 202474 and the MEK inhibitor PD 98059. Similarly, an increase in hematopoietic colony formation, though of a lesser magnitude was seen when MDS bone marrow progenitors were transfected with siRNAs against p38 MAPK. To further determine the role of cytokines in the pathogenesis of MDS, we also used bone marrow derived sera from the same MDS patients. Our studies show exposure to patient derived sera led to the phosphorylation/activation of p38 MAPK in normal hematopoietic progenitors when compared to sera from healthy volunteers. Our studies also demonstrate that bone marrow derived sera from MDS patients can inhibit erythroid and myeloid colony formation of normal hematopoietic progenitors. This inhibition can be reversed by blocking p38 MAPK using SD-282, other p38 inhibitors and siRNAs. This finding confirms the role of marrow cytokine /serum factors in the ineffective hematopoiesis seen in MDS and suggests the importance of p38 MAPK activation in this phenomenon. Thus our studies show the p38 MAPK may be a common effector of inhibitory cytokine signaling in normal and MDS hematopoietic cells. These results provide a strong rationale for using p38 inhibition as a novel treatment strategy for MDS. Supported by Harris Methodist Foundation Grant, VISN-17 New Investigator Grant and VA Research Corp Grant to AV." @default.
• W2994262466 created "2019-12-13" @default.
• W2994262466 creator A5033718619 @default.
• W2994262466 creator A5034688760 @default.
• W2994262466 creator A5039886481 @default.
• W2994262466 creator A5051335860 @default.
• W2994262466 creator A5063862150 @default.
• W2994262466 creator A5075590796 @default.
• W2994262466 creator A5087071457 @default.
• W2994262466 creator A5089074892 @default.
• W2994262466 creator A5089798406 @default.
• W2994262466 date "2004-11-16" @default.
• W2994262466 modified "2023-09-29" @default.
• W2994262466 title "Novel P38 MAP Kinase Inhibitor and Anti-P38 RNA Interference as Potential Therapeutic Approaches in Myelodysplastic Syndromes." @default.
• W2994262466 doi "https://doi.org/10.1182/blood.v104.11.470.470" @default.
• W2994262466 hasPublicationYear "2004" @default.
• W2994262466 type Work @default.
• W2994262466 sameAs 2994262466 @default.
• W2994262466 citedByCount "1" @default.
• W2994262466 crossrefType "journal-article" @default.
• W2994262466 hasAuthorship W2994262466A5033718619 @default.
• W2994262466 hasAuthorship W2994262466A5034688760 @default.
• W2994262466 hasAuthorship W2994262466A5039886481 @default.
• W2994262466 hasAuthorship W2994262466A5051335860 @default.
• W2994262466 hasAuthorship W2994262466A5063862150 @default.
• W2994262466 hasAuthorship W2994262466A5075590796 @default.
• W2994262466 hasAuthorship W2994262466A5087071457 @default.
• W2994262466 hasAuthorship W2994262466A5089074892 @default.
• W2994262466 hasAuthorship W2994262466A5089798406 @default.
• W2994262466 hasConcept C109159458 @default.
• W2994262466 hasConcept C184235292 @default.
• W2994262466 hasConcept C201750760 @default.
• W2994262466 hasConcept C203014093 @default.
• W2994262466 hasConcept C2778690821 @default.
• W2994262466 hasConcept C28328180 @default.
• W2994262466 hasConcept C502942594 @default.
• W2994262466 hasConcept C51551487 @default.
• W2994262466 hasConcept C57074206 @default.
• W2994262466 hasConcept C86803240 @default.
• W2994262466 hasConcept C95444343 @default.
• W2994262466 hasConcept C97029542 @default.
• W2994262466 hasConceptScore W2994262466C109159458 @default.
• W2994262466 hasConceptScore W2994262466C184235292 @default.
• W2994262466 hasConceptScore W2994262466C201750760 @default.
• W2994262466 hasConceptScore W2994262466C203014093 @default.
• W2994262466 hasConceptScore W2994262466C2778690821 @default.
• W2994262466 hasConceptScore W2994262466C28328180 @default.
• W2994262466 hasConceptScore W2994262466C502942594 @default.
• W2994262466 hasConceptScore W2994262466C51551487 @default.
• W2994262466 hasConceptScore W2994262466C57074206 @default.
• W2994262466 hasConceptScore W2994262466C86803240 @default.
• W2994262466 hasConceptScore W2994262466C95444343 @default.
• W2994262466 hasConceptScore W2994262466C97029542 @default.
• W2994262466 hasLocation W29942624661 @default.
• W2994262466 hasOpenAccess W2994262466 @default.
• W2994262466 hasPrimaryLocation W29942624661 @default.
• W2994262466 hasRelatedWork W1547736903 @default.
• W2994262466 hasRelatedWork W1990580490 @default.
• W2994262466 hasRelatedWork W2000302322 @default.
• W2994262466 hasRelatedWork W2002426440 @default.
• W2994262466 hasRelatedWork W2008532188 @default.
• W2994262466 hasRelatedWork W2067349642 @default.
• W2994262466 hasRelatedWork W2361004602 @default.
• W2994262466 hasRelatedWork W2419118008 @default.
• W2994262466 hasRelatedWork W2802110175 @default.
• W2994262466 hasRelatedWork W4230795789 @default.
• W2994262466 isParatext "false" @default.
• W2994262466 isRetracted "false" @default.
• W2994262466 magId "2994262466" @default.
• W2994262466 workType "article" @default.